Review Article
Sinonasal Manifestations in Cystic Fibrosis

Karin P. Q. Oomen and Max M. April

Division of Pediatric Otolaryngology-Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medical College, 428 East 72nd Street, Suite 100, New York, NY 10021, USA

Correspondence should be addressed to Max M. April, mma2005@med.cornell.edu

Received 24 January 2012; Revised 4 June 2012; Accepted 15 June 2012

Academic Editor: Leonard P. Rybak

Copyright © 2012 K. P. Q. Oomen and M. M. April. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cystic fibrosis is a genetic disease, characterized by accumulation of thickened mucous secretions in exocrine glands. Although the major clinical manifestations of the disease are pancreatic and pulmonary disease, the majority of cystic fibrosis patients will develop sinonasal manifestations as well. This paper outlines the etiology, evaluation, and management of the nasal and sinus manifestations in patients with cystic fibrosis.

1. Introduction

Cystic fibrosis (CF) is an autosomal recessively inherited disease, caused by mutations in the CF gene located at chromosome 7. The CF gene encodes the CF transmembrane regulator (CFTR), a membrane bound protein capable of chloride ion transport [1]. A deficiency of the CFTR leads to chloride channel dysfunction at the epithelial cells lining the airway and exocrine glands, causing accumulation of thickened mucous secretions.

Although the dominant clinical features of CF are lower respiratory tract infections and pancreatic insufficiency, the vast majority of CF patients will also develop chronic rhinosinusitis due to sinonasal mucus accumulation [2–5]. Because of the considerable morbidity associated with sinus disease and the growing belief that sinonasal involvement may worsen pulmonary manifestations, the otolaryngologist has become increasingly involved in evaluation and management of CF patients.

This paper will provide an aid in clinical decision making by outlining the etiology, evaluation, and management of the nasal and sinus manifestations in patients with CF from an evidence based perspective.

2. Etiology and Evaluation

Rhinosinusitis is an inflammatory process of multifactorial etiology, involving the mucosa of the nose and one or more sinus. Factors contributing to the pathology of rhinosinusitis are mucociliary impairment, infection, allergy, mucosal edema, and, rarely, physical obstructions caused by morphological or anatomical variation in the nasal cavity or paranasal sinus [6]. The prevalence of rhinosinusitis in the CF population borders on 100%, according to a combination of symptoms, physical and radiologic findings [3–5]. The high susceptibility for sinus disease in CF patients may be related to altered properties of their mucous secretions, leading to impaired mucociliary clearance. Obstruction of the ostia leads to ciliary injury, mucosal edema, and general inflammation, which is further exacerbated by chronic colonization, in most cases with pathogens of the upper and lower respiratory tract such as Pseudomonas species, Staphylococcus aureus, and nontypable Haemophilus influenzae [7]. Furthermore, genetic studies have suggested that the CFTR mutation responsible for CF might in itself be a predisposing factor for sinus disease, by demonstrating an increased occurrence of CFTR mutations in the general population with chronic rhinosinusitis [8, 9].

The most frequent presenting symptoms of sinus disease in CF are nasal congestion and purulent nasal discharge, but headache, mouth breathing, anosmia, and hyposmia related to chronic sinus disease are commonly reported as well. Physical findings may vary, but are mostly due to purulent drainage and mucosal changes resulting in nasal obstruction. Nasal polyps may be identified on anterior rhinoscopy or nasal endoscopy in up to 86% of children with CF, but
the frequency varies in different populations and study groups [10–16]. Other findings include swollen turbinates and lymphoid hyperplasia in the posterior pharynx.

Nearly all patients with CF show radiologic evidence of mucosal sinus disease, whether or not sinonasal symptoms are present [17]. To establish the relationship between CF and radiological sinus abnormalities more accurately, April et al. [18] studied the computed tomography (CT) scan findings of 58 CF patients. Bilateral medial displacement of the lateral nasal wall in the middle meatus and uncinate process demineralization were the most commonly encountered radiological findings, prevalent in 74% of patients. (Figure 1) Previous studies have shown that the extent of sinus disease on CT images does not correlate with symptom severity in patient with chronic rhinosinusitis [15, 19]. However, given the rate of anatomical variations and abnormalities of the sinus in CF, the CT scan remains of great value in the preoperative work-up of these patients, irrespective of its diagnostic role.

3. Management

3.1. Medical Management. As survival continues to improve for CF patients, management of sinonasal manifestations has become increasingly important. Medical management of sinusitis in CF generally consists of local and/or systemic anti-inflammatory medications and antibiotics. Hadfield et al. [20] have shown that local anti-inflammatory agents, such as nasal steroids, may reduce polyp size in patients with CF, although they did not demonstrate a significant reduction in associated sinus symptoms.

Systemic glucocorticoids are commonly used in CF patients to reduce pulmonary symptoms, and might have a beneficial effect on sinonasal manifestations as well. Unfortunately, no evidence exists on the effects of oral steroids on sinusitis in CF patients. A recent Cochrane review of randomized controlled trials of oral corticosteroids in CF patients demonstrates slowing of progression of pulmonary disease, reduction of hospitalization for respiratory exacerbations, and improved quality of life, but does not directly address the effect on sinonasal symptoms [21]. The positive effect of oral glucocorticoids on chronic sinusitis in the general population [22, 23] suggests a role for these agents in management of sinus disease in CF patients as well.

Recently, a randomized controlled trial by Ramsey et al. [24] demonstrated substantial improvements in lung function, rate of pulmonary exacerbations, and patient-reported respiratory symptoms associated with the use of a new therapeutic agent, the CFTR potentiator Ivacaftor, in a subset of CF patients. These findings might represent an important milestone in the development of treatments addressing the underlying cause of CF. Effects on sinonasal manifestations, however, were not measured.

Antibiotic therapy in CF is generally directed toward CF related organisms that occur in both the upper and lower airway. Both sputum and middle meatus cultures are used as a guide for antibacterial therapy, and previous studies have shown the most commonly cultured pathogens to be *Pseudomonas aeruginosa* and *Staphylococcus aureus* [25, 26]. CF patients generally use oral antibiotics such as ciprofloxacin or azithromycin as a prophylaxis to prevent infections of the lower and upper airway or to control present infections [27]. Inhaled therapy with antibiotics such as tobramycin, colistin, and aztreonam is often used as well in order to improve lung function by aiming at colonized bacteria, but their efficacy in treating upper airway manifestations remains unknown [28–30]. Unfortunately, aminoglycosides such as tobramycin are known to cause sensorineural hearing loss and damage to the labyrinth with long-term use [31], which is in itself another reason for the otolaryngologist to be involved in CF patient care. The efficacy of oral antibiotics in treatment of chronic rhinosinusitis in otherwise healthy patients [22] suggests a role for antibiotics in the CF population with sinus disease as well, and a previous study has demonstrated that long-term systemic treatment with macrolides may reduce nasal polyp size in patients with CF [32].

3.2. Surgery. Unfortunately, many CF patients will fail medical management of sinusitis, and approximately 20–25% of patients ultimately undergo sinus surgery [33]. As the survival of patients with CF increases, the number of CF patients requiring sinus surgery will likely grow. Sinus surgery is not only recommended because of medically intractable symptomatic nasal polyposis and trapped secretions in the sinus, but also as a preventive and preparatory measure for lung transplant candidates. After lung transplantation, a major cause of morbidity and mortality is *Pseudomonas aeruginosa* pneumonia, which is thought to originate from sinus colonization [2].

As in the general population, traditional techniques for sinus surgery in CF have included simple polypectomy and open ethmoidectomy or Caldwell-Luc procedures. Attempts at treatment of sinusitis in CF patients in the past with polypectomy alone have resulted in initial symptom relief but recurrence rates of more than 80% [34–36]. More extensive
The exact role of the CT scan in the diagnostic work-up of patients with sinonasal manifestations of CF has remained subject to debate. Although the definition of rhinosinusitis may be based on symptoms and signs only, many clinicians use CT scans to help define its actual presence. Previous studies have shown that the extent of sinus disease on CT images does not correlate with symptom severity in patients.
<table>
<thead>
<tr>
<th>Category</th>
<th>References</th>
<th>Description</th>
<th>Level of evidence</th>
<th>Evidence grade</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sinonasal manifestations in CF</td>
<td>[3, 4, 5]</td>
<td>Expert opinion</td>
<td>2b</td>
<td>D</td>
<td>Sinonasal manifestations are prevalent in almost all CF patients</td>
</tr>
<tr>
<td>Presence of nasal polyps in CF</td>
<td>[10–14, 16, 15]</td>
<td>Expert opinion</td>
<td>2b</td>
<td>D</td>
<td>Nasal polyps may occur in up to 86% of CF patients</td>
</tr>
<tr>
<td>Radiological evidence of sinus disease in CF</td>
<td>[17, 59]</td>
<td>Nonconsecutive cohort study</td>
<td>3b</td>
<td>C</td>
<td>Virtually all CF patients demonstrate radiological evidence of sinus disease</td>
</tr>
<tr>
<td>Radiological abnormalities</td>
<td>[17, 18]</td>
<td>Retrospective chart review</td>
<td>4</td>
<td>C</td>
<td>The most prevalent radiological abnormalities in CF are bilateral uncinate process demineralization and medial displacement of the lateral nasal wall</td>
</tr>
<tr>
<td>Failing of medical therapy</td>
<td>[33]</td>
<td>Retrospective cohort study</td>
<td>2b</td>
<td>B</td>
<td>Many CF patients will ultimately fail medical therapy and undergo sinus surgery</td>
</tr>
<tr>
<td>ESS as a treatment for sinus disease in CF</td>
<td>[11, 37–43]</td>
<td>Retrospective cohort studies, individual case control studies and retrospective chart reviews</td>
<td>2b, 3, 4</td>
<td>B-C</td>
<td>ESS is a safe and effective treatment of sinus disease in CF</td>
</tr>
<tr>
<td>Revision sinus surgery</td>
<td>[51]</td>
<td>Retrospective cohort study</td>
<td>2b</td>
<td>B</td>
<td>A high proportion of CF patients will eventually require revision sinus surgery</td>
</tr>
<tr>
<td>Risk factors for revision surgery</td>
<td>[51, 52, 53]</td>
<td>Retrospective cohort study</td>
<td>2b</td>
<td>B</td>
<td>The identification of factors associated with an increased likelihood of need for revision sinus surgery has resulted in equivocal outcomes</td>
</tr>
<tr>
<td>Effects of surgery on pulmonary outcomes</td>
<td>[55–58]</td>
<td>Lower quality cohort studies</td>
<td>4</td>
<td>C</td>
<td>There is an improvement of pulmonary symptoms and a reduced need for hospitalizations after sinus surgery in CF, but no differences in pulmonary function test outcomes</td>
</tr>
<tr>
<td>Postoperative complications</td>
<td>[38, 39]</td>
<td>Lower quality cohort studies</td>
<td>4</td>
<td>C</td>
<td>There is no association between sinus surgery in CF and increased rates of postoperative complications</td>
</tr>
<tr>
<td>Surgical revision rates</td>
<td>[53]</td>
<td>Lower quality cohort study</td>
<td>4</td>
<td>C</td>
<td>Surgical revision rates CF patients with polyps are much higher than in those without polyps</td>
</tr>
</tbody>
</table>
with chronic rhinosinusitis, both in the CF and the otherwise healthy population [15, 16, 19]. Studies on CT scan findings of the sinus in CF patients have established that specific abnormalities, such as bilateral uncinate process demineralization and medial displacement of the lateral nasal wall, might be CF defining, and should raise suspicion of CF in any patient with sinonasal symptoms, especially children [17, 18]. These findings suggest a diagnostic role of the CT scan in sinonasal manifestations of CF.

To the same extent, it remains uncertain whether culturing is an important diagnostic tool in sinus disease associated with CF. Both sputum and middle meatus cultures are currently used as a guide for antibiologic therapy, and previous studies have shown the most commonly cultured pathogens to be Pseudomonas aeruginosa and Staphylococcus aureus [25, 26]. However, further studies are required to comprehend the role of specific microorganisms in the pathogenesis of sinus disease in CF and the association of culture results with clinical severity.

Medical treatment for sinonasal manifestations in CF needs to be further studied to establish the role of both systemic antibiotics and anit-inflammatory agents such as glucocorticoids. Antibiotic therapy may need to be studied specifically for its potentiality of inflicting sensorineural hearing loss, and future treatment protocols might incorporate annual audiometry of CF patients on the basis of such studies.

When it comes to the effectiveness of ESS for sinus disease in CF, long-term results are few. There remains a need for prospective trials on the effect of sinus surgery in patients with CF. Outcome measures should not only focus on radiological appearance of the sinus and sinonasal symptoms, but also on quality of life and need for hospitalizations for upper and lower respiratory tract problems. Future research might also focus on new surgical techniques to treat sinonasal manifestations. The safety and efficacy of BCS in treatment of chronic rhinosinusitis in the otherwise healthy pediatric population suggest a potential role for BCS in the treatment of sinonasal manifestations of CF.

The increasing life expectancy of CF patients might raise the question if pediatric and adult CF populations require different treatment approaches with respect to sinonasal manifestations. Most studies on effects of ESS in CF have been carried out in mixed adult and pediatric populations. In order to differentiate between the effect of ESS on sinus disease in the pediatric and adult population, separate studies for each age group might be needed. Such studies might hold the promise for specific age appropriate surgical treatment of CF patients.

Given the high recurrence rate of sinus disease in this population, studies on perioperative management of CF patients undergoing sinus surgery are also needed, with a focus on pre and postoperative antibiotics and anti-inflammatory agents. Such studies might provide an aid in prevention of disease recurrence and revision procedures. The lack of effect of ESS on pulmonary function test results in previous retrospective studies [55, 56, 58] highlights the need for prospective assessment of pulmonary effects, as well as postoperative quality of life improvement and of adjunct medical therapy efficacy for pulmonary symptoms.

5. Summary

Sinonasal manifestations are prevalent in almost all patients with CF, whether represented by signs, symptoms, or radiologic findings (grade B, D evidence) [3–5]. Nasal polyps are the most frequently encountered findings on physical examination and may occur in up to 86% of patients (grade C-D evidence) [10–16]. Virtually all CF patients demonstrate radiological evidence of sinus disease, but the extent of disease does not correlate with symptom severity (grade C-D evidence) [17, 59]. The most prevalent radiological abnormalities in CF have shown to be bilateral uncinate process demineralization and medial displacement of the lateral nasal wall (grade C evidence) [17, 18].

Medical treatment of sinus disease in CF may consist of local and/or inflammatory agents and antibiotics. However, many patients will ultimately fail medical therapy and undergo sinus surgery (grade B evidence) [33]. ESS has been proven to be a safe and effective treatment of sinus disease in CF (grade B-C evidence) [11, 37–43]. Unfortunately, a high proportion of CF patients will eventually require revision surgery because of recurrence or persistence of sinus disease (grade C evidence) [51]. The identification of factors associated with an increased likelihood of need for revision sinus surgery has been aimed at by many studies, with equivocal outcomes (grade B-C evidence) [51–53]. Studies on the effect of sinus surgery on pulmonary function have shown improvement of pulmonary symptoms and a reduced need for hospitalization, but no differences in pulmonary function test outcomes (grade C evidence) [55–58]. No association has been found between sinus surgery and increased rates of postoperative complications, including hemorrhage (grade C evidence) [38, 39]. Surgical revision rates in patients with nasal polyps are much higher than in patients without polyps (grade C evidence) [53]. Evidence grades and conclusions are summarized in Table 1.

Authors’ Contribution

The authors have nothing to declare.

References


